The latest LEAP-002 trial results suggested that the study endpoints, including overall survival (OS), progression-free survival (PFS), and objective response rate (ORR), showed a trend of benefit; however, this study did not meet the prespecified significance for improved OS and PFS versus lenvatinib as a placebo 6 .
← all excerpts
Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors.
1
—
—